A fixed brain seeded amplification assay to complement neuropathological prion disease diagnosis
Journal of Neuropathology & Experimental Neurology · 2026
DOI: 10.1093/jnen/nlaf105 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuropathology & Experimental Neurology, 2026. Verfasst von Victoria Lewis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (RMH), The University of Melbourne, Parkville, VIC, Australia. Hauptthemen laut MEDLINE: Prion Diseases, Brain, Prions. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian National Creutzfeldt-Jakob, Australian Government Department of Health, Disability and Ageing.
Abstract (Originalsprache)
Prion diseases are rare neurodegenerative disorders that share misfolding of the normal cellular prion protein into disease-causing isoforms known as “prions” as the critical pathophysiological event. Definite diagnosis can only be achieved through neuropathological confirmation. The neuropathological features of prion disease are well described; however, some molecular subtypes are typified by characteristic neuropathological features that are subtle or absent. Prion seeding assays have excellent specificity and have considerably improved premortem diagnostic accuracy but they have reduced sensitivity for some uncommon prion disease molecular subtypes. We developed a formalin-fixed, paraffin-embedded tissue-based prion seeding assay to serve as a complementary diagnostic tool for prion diseases. Fixed brain tissue was prepared through an optimized process involving careful defacing of tissue blocks prior to sampling and then stepwise deparaffinization and homogenization. Fixed tissue homogenates are then tested in an adapted version of a diagnostic cerebrospinal fluid (CSF) prion seeding assay, which utilizes full-length recombinant hamster prion protein as substrate. Two examples illustrate the utility of the assay by confirming prion seeding in fixed brain tissue from previously neuropathologically misdiagnosed obligate carriers of 2 different prion protein gene mutations. The importance of careful tissue sampling to rigorously maintain the diagnostic specificity of this assay is also highlighted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine (RMH), The University of Melbourne, Parkville, VIC, Australia.
- Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR), The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
- The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
- Department of Anatomical Pathology, Alfred Health, Melbourne, VIC, Australia.
Förderung
- Australian National Creutzfeldt-Jakob
- Australian Government Department of Health
- Disability and Ageing
- The Australian National Creutzfeldt-Jakob Disease Registry
- Australian Government Department of Health, Disability and Ageing
Zitieren
APA
Lewis, V., Ellett, L., Lei, E., Stehmann, C., Birchall, I., Senesi, M., McLean, C., & Collins, S. J. (2026). A fixed brain seeded amplification assay to complement neuropathological prion disease diagnosis. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlaf105
Vancouver
Lewis V, Ellett L, Lei E, Stehmann C, Birchall I, Senesi M, et al. A fixed brain seeded amplification assay to complement neuropathological prion disease diagnosis. Journal of Neuropathology & Experimental Neurology. 2026. doi:10.1093/jnen/nlaf105
BibTeX
@article{Lewis2026,
author = {Lewis, Victoria and Ellett, Laura and Lei, Enie and Stehmann, Christiane and Birchall, Ian and Senesi, Matteo and McLean, Catriona and Collins, Steven J},
title = {A fixed brain seeded amplification assay to complement neuropathological prion disease diagnosis},
journal = {Journal of Neuropathology & Experimental Neurology},
year = {2026},
doi = {10.1093/jnen/nlaf105}
}
EUVIMED